Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s442, 2024. DOI: 10.25251/skin.8.supp.442. Disponível em: https://skin.dermsquared.com/skin/article/view/3141. Acesso em: 16 may. 2025.